Novavax (NVAX) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts NVAX Hot Sheet
Join SI Premium – FREE
Novavax (NASDAQ: NVAX) reported Q3 EPS of ($0.15), $0.01 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $8.4 million versus the consensus estimate of $6.42 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ACM Research (ACMR) Tops Q3 EPS by 6c ; Offers Guidance
- Lemonade (LMND) Tops Q3 EPS by 2c ; Offers Guidance
- Haemonetics (HAE) Tops Q2 EPS by 6c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
